Not yet treated | BCS | Mx with IBR | Mx without IBR | Chemotherapy | Hormonal treatment | Other | |
---|---|---|---|---|---|---|---|
DCISa | |||||||
Weeks 2–8 | 2.04 (1.44–2.88) | 0.81 (0.63–1.04) | 0.87 (0.58–1.32) | 0.95 (0.66–1.36) | 0.71 (0.08–6.32) | 0.27 (0.03–2.19) | NA |
Weeks 9–11 | 2.18 (1.31–3.61) | 0.72 (0.49–1.05) | 0.56 (0.28–1.10) | 1.36 (0.82–2.26) | NA | 2.13 (0.40–11.33) | NA |
Weeks 12–13 | 1.38 (0.61–3.13) | 0.80 (0.47–1.36) | 0.44 (0.15–1.29) | 1.38 (0.70–2.72) | NA | 18.32 (3.68–91.30) | NA |
Weeks 14–17 | 1.07 (0.37–3.11) | 0.53 (0.28–1.04) | 1.92 (0.78–4.74) | 1.40 (0.60–3.25) | 5.98 (0.57–62.65) | 2.13 (0.22–20.53) | NA |
Invasiveb | |||||||
Weeks 2–8 | 1.11 (0.84–1.48) | 0.93 (0.83–1.04) | 0.93 (0.74–1.16) | 1.01 (0.88–1.16) | 0.96 (0.82–1.12) | 1.23 (1.05–1.44) | 0.50 (0.25–0.98) |
Weeks 9–11 | 0.95 (0.60–1.50) | 0.93 (0.79–1.10) | 0.97 (0.70–1.36) | 1.11 (0.91–1.36) | 0.59 (0.45–0.76) | 1.92 (1.53–2.41) | NA |
Weeks 12–13 | 0.63 (0.27–1.45) | 0.91 (0.70–1.17) | 0.52 (0.28–0.96) | 0.90 (0.65–1.24) | 0.66 (0.45–0.95) | 3.01 (2.20–4.11) | NA |
Weeks 14–17 | 0.83 (0.48–1.45) | 0.75 (0.61–0.92) | 1.08 (0.73–1.59) | 1.11 (0.87–1.41) | 1.31 (1.01–1.70) | 1.26 (0.96–1.65) | 0.42 (0.13–1.38) |